Bright Minds Biosciences R&D Spending Growth & History (DRUG)
Bright Minds Biosciences's r&d spending was $11.1M for fiscal 2025.
View full Bright Minds Biosciences company overviewBright Minds Biosciences annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | $11.1M | $9.9M | +839.36% |
| 2024 | 2024-09-30 | $1.2M | −$3.8M | −76.40% |
| 2023 | 2023-09-30 | $5.0M | −$7.2M | −58.95% |
| 2022 | 2022-09-30 | $12.2M | $5.9M | +92.92% |
| 2021 | 2021-09-30 | $6.3M | $6.0M | +1679.33% |
| 2020 | 2020-09-30 | $354,852 | — | — |
Bright Minds Biosciences quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | $9.3M | $6.6M | +243.68% |
| Q2 2026 | 2026-03-31 | $13.0M | $10.5M | +409.06% |
| Q1 2026 | 2025-12-31 | $5.7M | — | — |
| Q4 2025 | 2025-09-30 | $4.8M | — | — |
| Q3 2025 | 2025-06-30 | $2.7M | — | — |
| Q2 2025 | 2025-03-31 | $2.6M | — | — |
Bright Minds Biosciences r&d spending trends
Over the last five fiscal years, Bright Minds Biosciences's r&d spending increased from $354,852 to $11.1M, a change of $10.7M. The latest reported quarter, Q3 2026, shows $9.3M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bright Minds Biosciences source filings ↗